Trial · NCT06451419
Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease
NCT06451419, Unknown, Juan Pablo Romero. MD, PhD
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease. Trials, record NCT06451419. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06451419
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease
- NCT number
- NCT06451419
- Status
- Unknown
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Juan Pablo Romero. MD, PhD
- Conditions
- Parkinson Disease
- Interventions
- Tests on non motor symptoms
- First posted
- 2024-06-11
- Last updated
- 2024-06-28
Source ClinicalTrials.gov
Registered outcomes135
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in non motor symptoms scale from baseline to 2 years | 2 years | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from baseline to 6 months | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from 6 months to 1 year | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from 12 months to 18 months | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Primary | Change in non motor symptoms scale from 18 months to 24 months | 6 months | To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. |
| Secondary | Change in Montreal Cognitive Assessment scale from baseline to 2 years | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
| Secondary | Change in Montreal Cognitive Assessment scale from18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. |
1 to 10 of 135Source ClinicalTrials.gov
See all 135 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06451419
GET https://conductscience.org/api/trials/v1/NCT06451419/registered?page=2